BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Uveal Melanoma readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Uveal Melanoma\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05987332-10793@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Darovasertib: Phase 2/3 readout est. (NCT05987332)
DESCRIPTION:Darovasertib\, phase 2/3\, Uveal Melanoma.\nStudy: IDE196 (Daro
 vasertib) in Combination With Crizotinib as First-line Therapy in Metastat
 ic Uveal Melanoma\nEstimated primary completion: 15 January 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/darovasertib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05987332
URL:https://assetmemo.bio/drug/darovasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03947385-10793@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Darovasertib: Phase 1/2 readout est. (NCT03947385)
DESCRIPTION:Darovasertib\, phase 1/2\, Uveal Melanoma.\nStudy: Study of IDE
 196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusi
 ons\nEstimated primary completion: 29 January 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/darovasertib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03947385
URL:https://assetmemo.bio/drug/darovasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05907954-10793@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Darovasertib: Phase 2 readout est. (NCT05907954)
DESCRIPTION:Darovasertib\, phase 2\, Uveal Melanoma.\nStudy: (Neo)Adjuvant 
 IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma\nEstimate
 d primary completion: 30 April 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/darovasertib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05907954
URL:https://assetmemo.bio/drug/darovasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06414590-10942@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 2 readout est. (NCT06414590)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 2\, Uveal Melanoma.\nStudy:
  Neoadjuvant Tebentafusp for Uveal Melanoma\nEstimated primary completion:
  August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tebenta
 fusp-tebn#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06414590
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06717126-2712@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:roginolisib: Phase 2 readout est. (NCT06717126)
DESCRIPTION:roginolisib\, phase 2\, Uveal Melanoma.\nStudy: A Randomised Ph
 ase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Mel
 anoma\nEstimated primary completion: December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/roginolisib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06717126
URL:https://assetmemo.bio/drug/roginolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07057596-10942@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 2 readout est. (NCT07057596)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 2\, Uveal Melanoma.\nStudy:
  Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma\nEstim
 ated primary completion: December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tebentafusp-tebn#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07057596
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06627244-10942@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20280217
DTEND;VALUE=DATE:20280218
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 2 readout est. (NCT06627244)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 2\, Uveal Melanoma.\nStudy:
  Study of Tebentafusp and Radioembolization in the Treatment of Metastatic
  Uveal Melanoma\nEstimated primary completion: 17 February 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06627244
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06070012-10942@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 2 readout est. (NCT06070012)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 2\, Uveal Melanoma.\nStudy:
  Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal 
 Melanoma\nEstimated primary completion: 30 September 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06070012
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06581406-10918@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Sturlimogene erparepvec: Phase 2/3 readout est. (NCT06581406)
DESCRIPTION:Sturlimogene erparepvec\, phase 2/3\, Uveal Melanoma.\nStudy: A
  Randomized\, Phase 2/3 Study to Investigate the Efficacy and Safety of RP
 2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adul
 t Patients With Metastatic Uveal Melanoma\nEstimated primary completion: J
 anuary 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sturlimo
 gene-erparepvec#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06581406
URL:https://assetmemo.bio/drug/sturlimogene-erparepvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06626516-10942@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 1/2 readout est. (NCT06626516)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 1/2\, Uveal Melanoma.\nStud
 y: Tebentafusp-tebn With LDT in Metastatic UM\nEstimated primary completio
 n: October 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tebe
 ntafusp-tebn#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06626516
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015190-10793@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Darovasertib: Phase 3 readout est. (NCT07015190)
DESCRIPTION:Darovasertib\, phase 3\, Uveal Melanoma.\nStudy: Neoadjuvant Da
 rovasertib in Primary Uveal Melanoma\nEstimated primary completion: Octobe
 r 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/darovasertib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0701
 5190
URL:https://assetmemo.bio/drug/darovasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276386-10942@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 2 readout est. (NCT07276386)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 2\, Uveal Melanoma.\nStudy:
  Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Me
 tastatic Uveal Melanoma\nEstimated primary completion: December 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tebentafusp-tebn#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07276386
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246149-10942@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 3 readout est. (NCT06246149)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 3\, Uveal Melanoma.\nStudy:
  Adjuvant Tebentafusp in High Risk Ocular Melanoma\nEstimated primary comp
 letion: November 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tebentafusp-tebn#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06246149
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07804186-10793@assetmemo.bio
DTSTAMP:20261121T004947Z
DTSTART;VALUE=DATE:20340331
DTEND;VALUE=DATE:20340401
SUMMARY:Darovasertib: Phase 3 readout est. (NCT07804186)
DESCRIPTION:Darovasertib\, phase 3\, Uveal Melanoma.\nStudy: Study of Adjuv
 ant Darovasertib and Crizotinib in Participants With Primary Non-metastati
 c Uveal Melanoma\nEstimated primary completion: March 2034. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/darovasertib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07804186
URL:https://assetmemo.bio/drug/darovasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
